Contact the Editorial Desk

Editorial correspondence

Peptide Division welcomes correspondence that improves the accuracy of the record: a citation quoted inaccurately, a regulatory reference that has changed, or a peer-reviewed publication about ipamorelin, CJC-1295, or sermorelin that should be added to the references page.

The most actionable notes include three elements: the specific page they concern, the exact passage in question, and the corrective citation — a DOI or PubMed ID wherever possible. That combination allows a proposed change to be verified against its source quickly.

Editorial mailbox: editors@peptidedivision.com

What this desk cannot do

To prevent unanswered messages from accumulating for the wrong reasons, several categories fall outside what this site can address.

Peptide Division is a literature digest, not a clinic or vendor. It cannot:

• Advise on, recommend, or comment on human use of any research compound discussed here.
• Suggest a dose, schedule, or route of administration for any person.
• Diagnose any condition, or assess whether a particular research finding applies to any individual.
• Sell, source, recommend, or help locate any peptide from any supplier.
• Answer questions from athletes subject to anti-doping rules about using these compounds, given that all three are prohibited under WADA S2.

Readers with clinical or health questions should consult a licensed clinician operating within their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.